Crunching the numbers for AMLX... Refresh in a moment for the full analysis.
Amylyx Pharmaceuticals, Inc. (AMLX)
Healthcare
mixed
$16.36
Updated: 2026-04-12
48
TradeApes Score
hold
Financial Strength
50
Mixed
Operating Trend
30
Weak
Valuation
50
Mixed
Capital Allocation
50
Mixed
Risk
80
Strong
Key Findings
+
Strong FCF growth — free cash flow up more than 20% year over year
−
Sharp revenue decline — sales down more than 15% year over year
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Create Free Account
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.